China plays a central role in the global pharmaceutical landscape as the leading supplier of active pharmaceutical ingredients (APIs) for the worldwide production of brand-name and generic medicines alike. The country has also increased the production of finished pharmaceutical products and has invested heavily in innovation in the pharmaceutical sector. National regulation of intellectual property rights has changed over time and new proposals are currently being discussed following the fast-evolving dynamics of the Chinese industry. How will that affect the global pharmaceutical landscape? What are the implications for public health policies and China’s international relations at the domestic, regional and global levels?
Peter Yu will present his recent paper examining China’s innovative turn and its implications for the global pharmaceutical landscape. He will present the latest proposed changes to the patent law and regulation on test data protection for pharmaceutical products. He will also provide an analysis of how they might affect innovation and access to medicines nationally and globally, and China’s position at international and regional trade forums. Yuanqiong Hu will then discuss the main findings and conclusions of the paper, with a focus on the implications for global policies on access to medicines.
- Peter Yu, Professor of Law, Professor of Communication and Director of the Center for Law and Intellectual Property at Texas A&M University
- Yuanqiong Hu, Postdoctoral Research Associate at the School of Law, SOAS, University of London and Senior Legal and Policy Advisor for the Access Campaign of Médecins Sans Frontières